Management of Single Elevated Bilirubin Levels

Initial Diagnostic Evaluation

The American Gastroenterological Association recommends obtaining fractionated bilirubin to determine if the elevation is predominantly conjugated or unconjugated, and ordering complete liver function tests including ALT, AST, ALP, GGT, and albumin to assess for liver injury and synthetic function 1
The European Association for the Study of the Liver suggests checking prothrombin time (PT) and INR to evaluate liver synthetic capacity, with a strength of evidence level of high 2, 1
Obtaining complete blood count with peripheral smear is recommended to assess for hemolysis if unconjugated hyperbilirubinemia is suspected, with a moderate level of evidence 1

For predominantly unconjugated hyperbilirubinemia, the American Association for the Study of Liver Diseases considers Gilbert's syndrome, which is diagnosed by calculating the proportion of conjugated bilirubin (should be less than 20-30% of total bilirubin), with a high level of evidence 3
Genetic testing for DNA mutations of uridine 5'-diphospho-glucuronyl-transferase can be considered for definitive confirmation of Gilbert's syndrome, with a moderate level of evidence 3
Evaluating for hemolysis with reticulocyte count, haptoglobin, and LDH is recommended, with a low level of evidence 1

For drug-induced liver injury, the National Institute of Diabetes and Digestive and Kidney Diseases recommends discontinuing the suspected drug if ALT ≥3× ULN with total bilirubin ≥2× ULN without initial finding of cholestasis, with a high level of evidence 3
For cholestatic DILI, repeating blood tests within 7-10 days is recommended, while for hepatocellular DILI, repeating within 2-5 days is suggested, with a moderate level of evidence 5
Monitoring closely if ALP >2× baseline without clear alternative explanation is advised, with a low level of evidence 4

If INR is prolonged, repeating within 2-5 days to confirm prolongation and determine trajectory is recommended, with a moderate level of evidence 3
Considering vitamin K supplementation to correct prolonged INR before assigning causality to liver dysfunction is suggested, with a low level of evidence 3
For patients with known cholestatic liver disease, non-adherence with ursodeoxycholic acid should be considered in causality assessment during evaluation of abrupt elevations in liver biochemistries, with a moderate level of evidence 3

The American College of Gastroenterology advises against overinterpreting albumin concentrations as a marker of liver disease severity, as albumin can be reduced in many clinical situations including sepsis, systemic inflammatory disorders, and malnutrition, with a high level of evidence 2
Avoiding delay in appropriate imaging in patients with conjugated hyperbilirubinemia is crucial, as early identification of biliary obstruction is critical for timely intervention, with a high level of evidence 1
Being aware that standard laboratory tests for hemolysis have poor specificity and sensitivity is important, with a low level of evidence 1